NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Decoy Therapeutics Inc. (DCOY) Stock Analysis

Decoy Therapeutics Inc. (DCOY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DCOY

$1.07

−$0.06 (−5.73%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DCOY with… →

DCOY Key Statistics

As of Oct 21, 2026
Trading
Open
$1.13
Previous Close
$1.14
Day's Range
1.04–1.16
52-Week Range
1.04–47.64
Volume
75.07K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.64
Valuation
Market Cap
$2.55M
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.21
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$12.52M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.39M
1-Year Return
−97.64%
Dividend and dates
Avg Volume
2.18M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DCOY closed at $1.07, −97.64% over 1 year.

Decoy Therapeutics Inc. (DCOY) has a market capitalization of $2.55M.

In fiscal 2025, DCOY reported revenue of $0.00.

DCOY Stock Return by Calendar Year

Decoy Therapeutics Inc. (DCOY) 10-year return: what $10,000 became

1 year
$10,000 $236
−97.64%
5 years
$10,000 $0.33
−99.997%
10 years
$10,000 $0.002
−99.99998%

If you had invested $10,000 in Decoy Therapeutics Inc. (DCOY) 10 years ago, at the close on October 21, 2016, it would have been worth $0.002 at the close on October 21, 2026: −99.99998% in total, −78.70% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−86.26%
2025−97.65%
2024−64.62%
2023−57.52%
2022−87.66%
2021−45.49%
2020−75.93%
2019−54.18%
2018−90.54%
2017−33.90%
2016 (partial year)−53.11%

As of October 21, 2026.

DCOY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$12.52M—
2024$0.00−$5.58M—
2023$0.00−$12.54M—
2022$0.00−$31.61M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.61M−$12.52M—
2024$0.00—−$5.73M−$5.58M—
2023$0.00—−$12.89M−$12.54M—
2022$0.00—−$22.98M−$31.61M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DCOY Valuation vs Biotechnology Median

Median of 608 stocks
MetricDCOYBiotechnology medianvs median
P/S ratio11.2113.3016% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Decoy Therapeutics Inc. (DCOY) carries a market capitalisation of $2.55M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 11.

The 52-week range on file runs from $1.04 to $47.64. DCOY last closed at $1.07 on October 21, 2026. That is −$0.06 (−5.73%) against the previous close. The latest close sits 3.17% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $12.52M.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 11.21. On price-to-sales that is 15.69% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 0.64. Daily returns over the trailing 10 years annualize to a volatility of 133.36%. The trailing one-year total return is −97.64%. Measured over 10 years, that is −78.70% a year compounded.

Growth & Income

No dividend is on file for DCOY.

2026 is still running; the total return is −86.26% year to date. The strongest complete calendar year on file is 2017 at −33.90%; the weakest is 2025 at −97.65%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Decoy Therapeutics Inc. (DCOY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Decoy Therapeutics Inc. DCOY $2.55M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Decoy Therapeutics Inc.

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.

Visit website →